Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and parkinson's disease

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor γ, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinson's disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinson's disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinson's disease on the effects of NSAIDs.

Original languageEnglish
Pages (from-to)1428-1434
Number of pages7
JournalCurrent Pharmaceutical Design
Volume14
Issue number14
DOIs
Publication statusPublished - May 2008

Fingerprint

Parkinsonian Disorders
Parkinson Disease
Neuroprotective Agents
Anti-Inflammatory Agents
Theoretical Models
Pharmaceutical Preparations
Aspirin
Pharmacology
Peroxisome Proliferator-Activated Receptors
Prostaglandin-Endoperoxide Synthases
Epidemiologic Studies
Nitric Oxide

Keywords

  • Cyclooxygenase
  • Dopamine quinone
  • Inflammation
  • Neuroprotection
  • Nitric oxide
  • Nonsteroidal anti-inflammatory drugs
  • Parkinson's disease
  • Peroxisome proliferator-activated receptor γ

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

@article{a4a7d86ffef147eeb55e0ae460388664,
title = "Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and parkinson's disease",
abstract = "A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor γ, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinson's disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinson's disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinson's disease on the effects of NSAIDs.",
keywords = "Cyclooxygenase, Dopamine quinone, Inflammation, Neuroprotection, Nitric oxide, Nonsteroidal anti-inflammatory drugs, Parkinson's disease, Peroxisome proliferator-activated receptor γ",
author = "Masato Asanuma and Ikuko Miyazaki",
year = "2008",
month = "5",
doi = "10.2174/138161208784480153",
language = "English",
volume = "14",
pages = "1428--1434",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "14",

}

TY - JOUR

T1 - Nonsteroidal anti-inflammatory drugs in experimental parkinsonian models and parkinson's disease

AU - Asanuma, Masato

AU - Miyazaki, Ikuko

PY - 2008/5

Y1 - 2008/5

N2 - A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor γ, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinson's disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinson's disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinson's disease on the effects of NSAIDs.

AB - A number of experimental studies using parkinsonian models have revealed that nonsteroidal anti-inflammatory drugs (NSAIDs) have neuroprotective properties against dopaminergic neurotoxicity not only by their cyclooxygenase-inhibiting effect but also by other specific properties or some unknown pharmacological effects. This article reviews heterogeneous pharmacological properties of NSAIDs including inhibitory effect against nitric oxide synthesis, agonistic action for peroxisome proliferator-activated receptor γ, or possible suppressive effects against dopamine quinone generation, and also reviews their neuroprotective effects in the experimental parkinsonian models and pathogenesis of Parkinson's disease. Several epidemiological studies recently clarified that the use of nonaspirin NSAIDs but not aspirin was associated with a lower prevalence of Parkinson's disease, in contrast with neuroprotective effects of aspirin in the experimental studies. It also discusses the discrepancy between results in the experimental parkinsonian models and epidemiological data in prevalence of Parkinson's disease on the effects of NSAIDs.

KW - Cyclooxygenase

KW - Dopamine quinone

KW - Inflammation

KW - Neuroprotection

KW - Nitric oxide

KW - Nonsteroidal anti-inflammatory drugs

KW - Parkinson's disease

KW - Peroxisome proliferator-activated receptor γ

UR - http://www.scopus.com/inward/record.url?scp=47249142027&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=47249142027&partnerID=8YFLogxK

U2 - 10.2174/138161208784480153

DO - 10.2174/138161208784480153

M3 - Article

C2 - 18537665

AN - SCOPUS:47249142027

VL - 14

SP - 1428

EP - 1434

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 14

ER -